Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Enorama Pharma ABOSTO:ERMA 28 PS Ratio is 9.40 as of Jul. 17, 2026, which is 70% below its 10-year median of 31.66. GuruFocus rates OSTO:ERMA with a GF Score™ of 28/100 and a GF Value™ of kr0.41 (Possible Value Trap). The stock has 4 warning signs investors should review. Among 954 Drug Manufacturers companies, Enorama Pharma AB ranks worse than 85.85% on this metric.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. As of today, Enorama Pharma AB's share price is kr0.282.
Enorama Pharma AB's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2026 was kr0.03. Hence, Enorama Pharma AB's PS Ratio for today is 9.40.
Good Sign:
Enorama Pharma AB stock PS Ratio (=8.5) is close to 1-year low of 8.5.
The historical rank and industry rank for Enorama Pharma AB's PS Ratio or its related term are showing as below:
OSTO:ERMA'
s PS Ratio Range Over the Past 10 Years
Min: 2.45 Med: 31.66 Max: 508.16
Current: 9.4
During the past 12 years, Enorama Pharma AB's highest PS Ratio was 508.16. The lowest was 2.45. And the median was 31.66.
OSTO:ERMA's PS Ratio is ranked worse than 85.85% of 954
companies
in the Drug Manufacturers industry
Industry Median: 2.325
vs OSTO:ERMA: 9.40
Enorama Pharma AB revenue per share has been in decline for the last 5 years.
During the past 12 months, the average Revenue per Share Growth Rate of Enorama Pharma AB was -89.70% per year.
During the past 3 years, the average Revenue per Share Growth Rate was -57.30% per year.
During the past 5 years, the average Revenue per Share Growth Rate was -37.00% per year.
During the past 12 years, Enorama Pharma AB's highest 3-Year average Revenue per Share Growth Rate was 13.10% per year. The lowest was -57.30% per year. And the median was -32.30% per year.
Back to Basics: PS Ratio
Enorama Pharma AB (OSTO:ERMA) PS Ratio Explanation
The PS Ratio is an excellent valuation indicator if you want to compare a stock with its historical valuation or with the stocks in the same industry. The PS Ratio works especially well when you want to compare the stock's current valuation with its historical valuation. The PS Ratio is a great valuation tool for evaluating cyclical businesses where the PE Ratio works poorly. It works the best when comparing the current valuation with the historical valuation because over time, a company's profit margin tends to revert to the mean.
When the PS Ratio is applied to the whole stock market, it can be used to evaluate the current market valuation and projected returns. In this case, the price is the total market cap of all stocks that are traded, and sales are the GDP of the country. This is how Warren Buffett estimates the broad market valuation and project future returns.
The PS Ratio does not tell you how cheap or expensive the stock is. It cannot be used to compare companies in different industries. It works better for companies within the same industry because these companies tend to have similar capital structures and profit margins. It works the best when comparing a company with itself in the past.
Enorama Pharma AB PS Ratio Related Terms
Enorama Pharma AB PS Ratio Historical Data
* Premium members only.
The historical data trend for Enorama Pharma AB's PS Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Enorama Pharma AB's PS Ratio, along with its competitors' market caps and PS Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Enorama Pharma AB PS Ratio vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Enorama Pharma AB's PS Ratio distribution charts can be found below:
* The bar in red indicates where Enorama Pharma AB's PS Ratio falls into.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. It is a ratio widely used to value stocks and it was first used by Ken Fisher.
Enorama Pharma AB's Share Price of today is kr0.282. Enorama Pharma AB's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was kr0.03.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
Enorama Pharma AB (OSTO:ERMA) has a PS Ratio of 9.40 as of Jul. 17, 2026. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on Enorama Pharma AB and its competitors. This is 70% below median its historical median of 31.66. Over the past decade, Enorama Pharma AB's PS Ratio has ranged from 2.45 to 508.16. According to the industry distribution chart, Enorama Pharma AB ranks #819 out of 954 companies in the Drug Manufacturers industry, placing it in the top 85.8%.
Is Enorama Pharma AB's PS Ratio too high?
Enorama Pharma AB's current PS Ratio of 9.40 is 70% below median its 10-year median of 31.66. Over the past 10 years, this metric has ranged from a low of 2.45 to a high of 508.16. The Drug Manufacturers industry median PS Ratio is 2.33. Enorama Pharma AB's value of 9.40 is 304.3% above this industry median. Based on the distribution chart, Enorama Pharma AB ranks #819 out of 954 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Enorama Pharma AB has a GF Score™ of 28/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Enorama Pharma AB's PS Ratio compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Enorama Pharma AB ranks #819 out of 954 companies for PS Ratio. This places Enorama Pharma AB in the lower half of its industry. The industry median PS Ratio is 2.33. Enorama Pharma AB's value of 9.40 is 304.3% above this benchmark. Historically, Enorama Pharma AB's own PS Ratio has ranged from 2.45 to 508.16 over the past decade. While the company's 10-year median is 31.66 vs. the industry median of 2.33, Enorama Pharma AB has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PS Ratio for a Drug Manufacturers company?
The median PS Ratio among Drug Manufacturers companies is 2.33, based on 954 companies in the industry. Companies in the top quartile (top 25%) have a PS Ratio significantly above this median, while those in the bottom quartile fall well below. However, PS Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Enorama Pharma AB's current PS Ratio of 9.40 is 304.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PS Ratio mean?
A high PS Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on Enorama Pharma AB and its competitors. For the Drug Manufacturers industry, the median PS Ratio is 2.33 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Enorama Pharma AB's current PS Ratio is 9.40, which is 70% below median its own 10-year median of 31.66. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Enorama Pharma AB stock overvalued right now?
Based on GuruFocus' analysis, Enorama Pharma AB (OSTO:ERMA) is currently considered Possible Value Trap. The stock's GF Value™ is kr0.41, compared to a current price of kr0.28 — trading 31.2% below its estimated fair value. The current PS Ratio is 9.40, which is 70% below median its 10-year median of 31.66 and 304.3% above the Drug Manufacturers industry median of 2.33. Enorama Pharma AB's overall GF Score™ is 28/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PS Ratio calculated?
PS Ratio is calculated from a company's financial statements. For Enorama Pharma AB (OSTO:ERMA), the current PS Ratio is 9.40 as of Jul. 17, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Enorama Pharma AB (OSTO:ERMA) Overvalued in 2026?
Based on GuruFocus' analysis, Enorama Pharma AB stock appears to be undervalued.
The current stock price of kr0.28 is trading 31.2% below its estimated GF Value™ of kr0.41.
GuruFocus considers Enorama Pharma AB to be Possible Value Trap.
Key valuation signals for OSTO:ERMA:
PS Ratio: 9.40 (70% below median its 10-year median of 31.66)
GF Value™: kr0.41 vs. price of kr0.28 (31.2% below fair value)
Industry Position: 304.3% above the Drug Manufacturers median (#819 of 954)
No single metric tells the full story. See the OSTO:ERMA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Enorama Pharma AB is a pharmaceutical company that focuses on consumer-friendly medicated chewing gum containing generic substances. It provides medicated gums containing generic pharmaceutical substances, developed through its ChewMed technology platform.
28GF Score
Get the complete analysis for OSTO:ERMA
PS Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
OSTO:ERMA has been successfully added to your 
